The biggest challenges currently facing companion diagnostic advancement

Area of Science:

• Oncology
• Molecular Diagnostics
• Personalized Medicine

Background:

• The pharmaceutical industry faces low productivity, making personalized medicine and companion diagnostics attractive.
• The oncology community is optimistic about molecular diagnostics for personalized cancer therapy.
• Personalized medicine aims to improve drug development, diagnostics, and patient treatment selection.

Purpose of the Study:

• To explore the challenges hindering personalized medicine and companion diagnostics in oncology.
• To discuss the impact of these challenges on clinical implementation.
• To suggest mitigation strategies for overcoming these obstacles.

Main Methods:

• Literature review and expert analysis of current challenges in personalized medicine.
• Exploration of biological, pre-analytical, and analytical factors.
• Examination of the gap between clinical, pharmaceutical, and diagnostic fields.

Main Results:

• Key challenges include limited understanding of cancer biology and preclinical models.
• Pre-analytical variables and analytical discrepancies significantly impact diagnostic accuracy.
• A substantial gap exists in understanding between clinical/pharmaceutical and diagnostic sectors.

Conclusions:

• Addressing challenges in biology, pre-analytical/analytical factors, and interdisciplinary communication is crucial.
• Overcoming these hurdles is essential for realizing the potential of personalized cancer therapy.
• Mitigation strategies are needed to pave the way for successful personalized medicine implementation.